COMBINED THERAPY WITH GROWTH-HORMONE AND OXANDROLONE IN ADOLESCENT GIRLS WITH TURNER SYNDROME

Five adolescent girls with Turner syndrome (mean age 13.9 years, mean bone age 12.0 years) were treated with both recombinant human growth h ormone (rhGH) and oxandrolone for 2 years with an average increment in height of 13.4 cm. The mean bone age advanced by only 1.2 years, prov iding an increase in the mean estimated mature height of 9.2 cm. We co nclude that rhGH and oxandrolone benefit older teenagers with Turner s yndrome because of an increased growth rate with slow progression of s keletal maturation.